blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2336141

EP2336141 - PHOSPHORAMIDATE ALKYLATOR PRODRUGS [Right-click to bookmark this link]
Former [2011/25]Phosphoramidate alkylator prodrugs
[2015/34]
StatusNo opposition filed within time limit
Status updated on  03.02.2017
Database last updated on 21.03.2026
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Threshold Pharmaceuticals, Inc.
170 Harbor Way, Suite 300
South San Francisco, CA 94080 / US
[2012/42]
Former [2011/25]For all designated states
Threshold Pharmaceuticals, Inc.
1300 Seaport Boulevard, 5th Floor
Redwood City, CA 94063 / US
Inventor(s)01 / Matteucci, Mark
135 Fawn Lane
Portola Valley, CA 94028 / US
02 / Duan, Jian-Xin
628 Marcie Circle
South San Francisco, CA 94080 / US
03 / Jiao, Hailong
861 Comet Drive
Foster City, CA 94404 / US
04 / Kaizerman, Jacob
P. O. Box 2498
Menlo Park, CA 94026 / US
 [2016/13]
Former [2011/25]01 / Matteucci, Mark
135 Fawn Lane
Portola Valley, CA 94028 / US
02 / Duan, Jian-Xin
628 Marcie Circle
South San Francisco, CA 94080 / US
03 / Jiao, Hailong
861 Comet Drive
Foster City, CA 94404 / US
04 / Kaizerman, Jacob
P. O. Box 2498
Menlo Park, CA 94026 / US
Representative(s)Campbell, Patrick John Henry
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[2016/13]
Former [2011/25]Campbell, Patrick John Henry
J.A. Kemp & Co. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date11157963.729.06.2006
[2011/25]
Priority number, dateUS20050695755P29.06.2005         Original published format: US 695755 P
[2011/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2336141
Date:22.06.2011
Language:EN
[2011/25]
Type: A3 Search report 
No.:EP2336141
Date:14.09.2011
Language:EN
[2011/37]
Type: B1 Patent specification 
No.:EP2336141
Date:30.03.2016
Language:EN
[2016/13]
Search report(s)(Supplementary) European search report - dispatched on:EP17.08.2011
ClassificationIPC:C07F9/6506, A61K31/675, A61P35/00, C07F9/6539, A61K31/337, A61K31/513, A61K31/7068, A61K33/24
[2015/33]
CPC:
A61K31/675 (EP,US); C07F9/24 (KR); A61K31/337 (EP,US);
A61K31/513 (EP,US); A61K31/685 (KR); A61K31/7068 (EP,US);
A61P1/00 (EP); A61P1/02 (EP); A61P1/04 (EP);
A61P1/18 (EP); A61P11/00 (EP); A61P11/06 (EP);
A61P13/08 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P27/16 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P7/04 (EP);
A61P7/06 (EP); A61P9/00 (EP); C07F9/645 (KR);
C07F9/6506 (EP,US); C07F9/65397 (US); C07F9/6564 (KR);
A61K33/243 (EP,US); A61K51/00 (EP,US) (-)
Former IPC [2011/25]C07F9/6506, A61K31/675, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/13]
Former [2011/25]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL14.03.2012
BA14.03.2012
HR14.03.2012
MK14.03.2012
RS14.03.2012
TitleGerman:PHOSPHORAMIDAT-ALKYLATOR-PRODRUGS[2011/37]
English:PHOSPHORAMIDATE ALKYLATOR PRODRUGS[2015/34]
French:PRODROGUES D'ALKYLATEUR DE PHOSPHORAMIDATE[2011/37]
Former [2011/25]Phosphoramidat-Alkylator-Prodrugs
Former [2011/25]Phosphoramidate alkylator prodrugs
Former [2011/25]Prodrogues d'alkylateur de phosphoramidate
Examination procedure14.03.2012Examination requested  [2012/17]
27.09.2012Amendment by applicant (claims and/or description)
05.10.2012Despatch of a communication from the examining division (Time limit: M04)
01.02.2013Reply to a communication from the examining division
03.07.2013Despatch of a communication from the examining division (Time limit: M02)
13.09.2013Reply to a communication from the examining division
30.06.2014Despatch of a communication from the examining division (Time limit: M02)
12.08.2014Reply to a communication from the examining division
27.11.2014Despatch of a communication from the examining division (Time limit: M02)
04.02.2015Reply to a communication from the examining division
22.04.2015Despatch of a communication from the examining division (Time limit: M02)
24.06.2015Reply to a communication from the examining division
22.07.2015Communication of intention to grant the patent
01.12.2015Fee for grant paid
01.12.2015Fee for publishing/printing paid
03.02.2016Information about intention to grant a patent
03.02.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06786161.7  / EP1896040
Divisional application(s)EP12182263.9   Application deemed to be withdrawn  : 02.10.2012
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060786161) is  19.08.2010
Opposition(s)03.01.2017No opposition filed within time limit [2017/10]
Fees paidRenewal fee
11.03.2011Renewal fee patent year 03
11.03.2011Renewal fee patent year 04
11.03.2011Renewal fee patent year 05
13.06.2011Renewal fee patent year 06
14.06.2012Renewal fee patent year 07
10.06.2013Renewal fee patent year 08
31.03.2014Renewal fee patent year 09
10.06.2015Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.06.2006
AT30.03.2016
BE30.03.2016
BG30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
IE29.06.2016
LU29.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
[2018/38]
Former [2018/29]HU29.06.2006
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
TR30.03.2016
IE29.06.2016
LU29.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2018/28]HU29.06.2006
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
IE29.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/37]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
IE29.06.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/07]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/03]AT30.03.2016
BE30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/51]AT30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/50]AT30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/49]EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
SE30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/48]FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/44]FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
GR01.07.2016
Former [2016/39]FI30.03.2016
LT30.03.2016
LV30.03.2016
SE30.03.2016
GR01.07.2016
Former [2016/36]FI30.03.2016
LT30.03.2016
GR01.07.2016
Former [2016/35]FI30.03.2016
GR01.07.2016
Documents cited:Search  No relevant documents disclosed
Examination  Quotations from Board of Appeal Decisions regarding deletions from multiple "R groups"
   F. MENG ET AL: "Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302", MOLECULAR CANCER THERAPEUTICS, vol. 11, no. 3, 1 March 2012 (2012-03-01), pages 740 - 751, XP055039520, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-11-0634

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-11-0634
by applicantUS2004009667
 US2005008161
 US2005041959
 US2005042095
 US4908356
 US5306727
 US5403932
 US5190929
 US5472956
 US6656926
 US2003008850
 US5622936
 US2005003370
 US63899505
 WO2004009667
 US5750782
 US5780585
 US5872129
 US6251933
 WO2004085421
 WO2004085361
 US2004254103
 US2005043244
 US2005047314
 WO2005076888
 US2005008161
 US34663206
 WO2006015191
 WO2006015263
 WO2006001007
   HARDMAN ET AL.: "The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL, pages: 1389 - 1399
   BERGE, S.M. ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104

DOI:   http://dx.doi.org/10.1002/jps.2600660104
   PATANI ET AL., CHEM. REV., vol. 96, 1996, pages 3147 - 76
   BURGER, A. PROG. DRUG RES., vol. 37, 1991, pages 287 - 371
   NOGRADY: "Medicinal Clientistry,4 Biochemical Approach", 1985, OXFORD UNIVERSITY PRESS, pages: 388 - 392
   DE JAEGER ET AL., BR J CANCER., vol. 84, no. 9, 2001, pages 1280 - 5
   ROFSTAD ET AL., BR J CANCER., vol. 80, no. 11, 1999, pages 1697 - 707
   WORKMAN ET AL., CANCER AND METAST. REV., vol. 12, 1993, pages 73 - 82
   BORCH ET AL., J. MED. CHEM., vol. 43, 2000, pages 2258 - 65
   HERNICK ET AL., J. MED. CHEM., vol. 45, 2002, pages 3540 - 8
   HERNICK ET AL., J. MED. CHEM., vol. 46, 2003, pages 148 - 54
   PAPOT ET AL., CURR. MED. CHEM., vol. 2, 2002, pages 155 - 85
   ENGLE ET AL., J. MED. CHEM., vol. 25, 1987, pages 1347 - 57
   BORCH ET AL., J. MED. CHEM.
   ROSEN ET AL., CLIN CANCER RES., vol. 10, no. 11, 2004, pages 3689 - 98
   KYLE ET AL., CANCER RES., vol. 64, no. 17, 2004, pages 6304 - 9
   WEST ET AL., CANCER CHEMOTHER. PHARMACOL., vol. 20, no. 2, 1987, pages 109 - 14
   DEGROOT ET AL., CURRENT MED. CHEM., vol. 8, 2001, pages 1093 - 1122
   "Remington's Pharmaceutical Sciences", 1984, MACK PUBLISHING COMPANY
   BIOCHEM. PHARMACOL., vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 947 - 954
   VENDETTI: "Pharmacological Basis of Cancer Chemotherapy", 1975, WILLIAMS AND WILKINS, article "Relevance of Transplantable Animal-Tumor Systems to the Selection of New Agents for Clinical Trial"
   SIMPSON HERREN ET AL.: "Evaluation of lit Vivo Tumor Models for Predicting Clinical Activity for Anticancer Drugs", PROC. AM. ASSOC. CANCER RES., vol. 26, 1985, pages 330
   "Physician's Desk Reference", 2003, MEDICAL ECONOMICS COMPANY, INC.
   INTERNATIONAL AGENCY FOR RESEARCH ON CANCER MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISK OF CHEMICALS TO HUMANS, vol. 9, 1975, pages 286
   INTERNATIONAL AGENCY FOR RESEARCH ON CANCER MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISK OF CHEMICALS TO HUMANS, vol. 50, 1990, pages 415
   SMITH ET AL., CANCER LETTERS, vol. 141, 1999, pages 85
   CAVALLERI ET AL., J. HET. CHEM., vol. 9, 1972, pages 979
   HAY ET AL., J. MED. CHEM., vol. 46, 2003, pages 169 - 82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.